- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
Teva's asset received FDA Orphan Drug and Fast Track designations after announcing an acquisition from Tel Aviv.
3 reports, 2 independent
Updated Aug 28
Gone quiet
- Reports
- 3
- Developments
- 1
- Repetition
- 67%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Teva's asset received FDA Orphan Drug and Fast Track designations after announcing an acquisition from Tel Aviv.
Who's involved
What this event is mainly aboutKeep exploring
Part of
A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.Also in this story
- A partnership with BARDA has accelerated the development of SCY-247 for the company.
- A company plans to submit regulatory applications to the FDA, EMA, and Australian TGA.
- Approval leads to procurement process initiation.
- UroGen Pharma Ltd., headquartered in Princeton, is seeking FDA approval for its products for the U.S. market.
The entities involved
-
Teva Pharmaceutical Industries Ltd.
Israeli pharmaceutical company
Nothing else this week.
- FDA